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Leishmania DNA–positive samples in
the Nubian mummies (12.9%) sug-
gests that leishmaniasis was endemic
in Nubia during the Early Christian
period and, in light of the data on the
ancient Egyptian mummies, probably
already several thousand years before.
Taken together, our results support the
theory that Sudan could have been
indeed the original focus of visceral
leishmaniasis (4).
Our study shows a completely new
aspect of molecular paleopathology.
The detection of ancient pathogen
DNA is not only used to identify a
certain disease and gain information
on its frequency and evolutionary ori-
gin but also to trace back cultural con-
tacts and their role in the transmission
and spread of infectious diseases. 
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Tickborne
Encephalitis Virus,
Northeastern Italy
To the Editor: Approximately
3,000 cases of tickborne encephalitis
virus (TBEV) disease are registered
annually in Europe (1). In Italy,
indigenous TBEV infection cases
have been only sporadically recorded
from 1975 through 2001; in addition,
serologic investigations in popula-
tions at risk in northern Italy have
shown only a low prevalence of spe-
cific antibodies (0.6%–5%) (2,3). A
surveillance system for TBEV infec-
tions was started after autochthonous
TBEV was recognized in late summer
and fall 2003 in Friuli-Venezia Giulia
(FVG), a small region of northeastern
Italy with nearly 1 million inhabitants
(4). Surveillance is based on system-
atic microbiologic screening of all
patients referred to the emergency
departments of regional hospitals for
suspected community-acquired cen-
tral nervous system infections or fever
and headache with a history of tick
bite in the past 6 weeks. Screening for
TBEV was performed on sera or cere-
brospinal fluid (CSF) by enzyme
immunoassay (Enzygnost Anti-TBE
virus Ig, Dade Behring Marburg
GmbH, Marburg, Germany) and
repeated on convalescent-phase sera.
Demonstration of specific immuno-
globulin M (IgM) in serum or CSF in
the acute phase or >4-fold rise in
serum antibody titer in the convales-
cent phase was interpreted as an indi-
cator of recent TBEV infection. For
surveillance purposes, TBEV infec-
tion was defined when hemagglutina-
tion inhibition antibody test and neu-
tralization assay by a reference labo-
ratory confirmed ELISA results (5).
Data were collected at a regional ref-
erence center, where cases were clas-
sified as possible, probable, and con-
firmed, according to the new TBEV
case definition (6).
Figure. PCR amplification of a 120-bp fragment of kinetoplastid mitochondrial DNA of
Leishmania spp. in Egyptian and Nubian mummies. Lane 1, 50-bp ladder; lanes 2–8,
mummy samples; lanes 9,10, extraction controls; lane 11, PCR controls. Lane 6 provides
a positive amplification product of the expected size.LETTERS
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From July 2003 through
November 2005, 20 cases of TBEV
infection were detected; their demo-
graphic, epidemiologic, and clinical
characteristics are given in the Table.
Cases occurred throughout the year,
with a biphasic peak in June and
September–November. A biphasic
clinical course was reported in 10
patients. The median period between
tick bite and date of referral to hospi-
tal was 22 days (range 15–46 days).
Seventeen cases were classified as
confirmed, 2 as probable, and 1 case
could not be classified because symp-
toms started after tick season
(December) (6). Two patients were
coinfected with Borrelia burgdorferi.
The most common symptoms were
fever, headache, nausea, vomiting,
and myalgia; the most common cen-
tral nervous system signs were stiff
neck, irritability, and limb paresis.
Five patients only reported headache
and fever without neurologic signs.
Lumbar puncture, performed in 15
patients, showed mild pleocytosis with
neutrophil predominance in 13 pa-
tients, elevated protein level in 14 pa-
tients, and normal glucose level in all.
The clinical syndrome was classi-
fied, in accordance with Kaiser et al.,
into febrile form (4 cases), aseptic
meningitis (3 cases), encephalitis (2
cases), meningoencephalitis (8 cases),
and meningoencephalomyelitis (3
cases) (7). None of the patients died,
but 3 required respiratory support in
the intensive care unit. Outcome was
favorable for 9 patients; major neuro-
logic sequelae were observed in 6 and
minor sequelae in 5.
During the past 20 years, TBEV
has reemerged in several European
areas that had been disease free (1,8).
In FVG, which borders disease-
endemic areas such as Slovenia and
Austria, the first cases of TBEV infec-
tion were documented recently (4).
Several explanations, in addition to
the well-established role of climate
change, can be proposed (1). First, in
Slovenia, after the end of the
Communist regime, recreational
activities increased considerably, with
the creation of natural parks and hunt-
ing grounds, densely populated with
deer, chamois, rodents, foxes, and
other wild animals that can easily
cross national borders (9). Second,
after the 1976 earthquake that
destroyed a large number of mountain
villages in FVG, economic activities
were progressively concentrated in
the plains of the region, which rapidly
increased urbanization of the plains
towns. As a consequence, the moun-
tains in the northern part of the region
were progressively abandoned by
humans and returned to wilderness. A
final possible explanation is that
TBEV cases were undiagnosed
because awareness among local
physicians was low; however, this
variable likely played a minor role,
since a recent serologic survey of per-
sons at high risk (forest rangers)
yielded a low positivity ratio (3). If
even workers at risk had a low sero-
prevalence, TBEV cases were likely
uncommon in the region.
The implementation of a regional
active surveillance system allows the
highest sensitivity in assessing the
epidemiologic features of TBEV
infections, which are characterized by
highly disease-endemic microfoci in
areas free of the problem (10).
Precisely defining areas where risk is
particularly will lead to optimal use ofLETTERS
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prevention programs and design of
educational programs for residents,
tourists, and healthcare workers.
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Alex Langmuir 
and CDC
To the Editor: We were surprised
and disappointed by the brevity of
your article commemorating the 60th
anniversary of the establishment of
the Communicable Disease Center
(CDC) (1). We realize that the accom-
plishments of the center and its deriv-
ative agencies are vast and that to give
them full recognition would require
far more space in Emerging Infectious
Diseases than might be feasible.
Nevertheless, your article that appro-
priately identified Joe Mountin as the
administrative “father” of the center
omitted any mention of Alex
Langmuir, arguably the most influen-
tial of the infectious disease leaders
over the years. Langmuir’s creation
and direction of the Epidemic
Intelligence Service epitomized
CDC’s role in infectious diseases. His
legacy deserves recognition in any
chronicle of CDC, no matter how
short.
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In response: We thank Drs.
Winkelstein and Reingold for their
comment regarding our article on the
60 years of CDC’s progress in the area
of infectious diseases. We certainly
agree that Dr. Alexander Langmuir
has made enormous contributions to
this area, which we fully respect, We
further agree that a more comprehen-
sive approach would have required far
more space than allotted for these
types of commentaries. Allow us to
emphasize that the omission of Dr.
Langmuir and many other outstanding
colleagues was not an oversight but an
effort on our part to abbreviate an
exceptionally long list of these
deserving persons. We are looking
forward to opportunities to provide a
more comprehensive overview in
which many of them will be appropri-
ately recognized.
Tanja Popovic*
*Centers for Disease Control and
Prevention, Atlanta, Georgia, USA
Address for correspondence: Tanja Popovic,
Centers for Disease Control and Prevention,
1600 Clifton Rd, Mailstop D50, Atlanta, GA
30333, USA; email: txp1@cdc.gov